A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations (SOHO-02)
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Bayer HealthCare Pharmaceuticals Inc
The purpose of this study is to look at how well the new study drug works compared to standard medical care in participants with non-small cell lung cancer
Enrollment Form
This study is currently enrolling.